Cancer Diagnostics Market Size, Share Detailed Report 2025 to 2034

Report Id: 1726 Pages: 180 Last Updated: 19 December 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Cancer Diagnostics Market -

Cancer Diagnostics Market By Product-

  • Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
  • Others
  • Instruments
  • Pathology based Instrument
    • Slide Staining Systems
    • Tissue Processing Systems
    • Cell Processors
    • PCR Instruments
    • NGS Instruments
    • Microarrays
    • Other Pathology-based Instruments
  • Imaging Instruments
  • Biopsy Instruments 

https://www.insightaceanalytic.com/images_data/771603113.JPG

Cancer Diagnostics Market By Technology-

  • IVD Testing
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-generation Sequencing (NGS)
  • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Others
  • Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound
  • Biopsy Technique

Cancer Diagnostics Market By Application-

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Cancer Diagnostics Market By End User-

  • Hospitals
  • Diagnostics Laboratories

Cancer Diagnostics Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Cancer Diagnostics Market Snapshot

Chapter 4. Global Cancer Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:

5.2.1. Consumables

5.2.1.1. Antibodies
5.2.1.2. Kits & Reagents
5.2.1.3. Probes
5.2.1.4. Other Consumables

5.2.2. Instruments

5.2.2.1. Pathology-based Instruments

5.2.2.1.1. Slide Staining Systems
5.2.2.1.2. Tissue Processing Systems
5.2.2.1.3. Cell Processors
5.2.2.1.4. PCR Instruments
5.2.2.1.5. NGS Instruments
5.2.2.1.6. Microarrays
5.2.2.1.7. Other Pathology-based Instruments

5.2.2.2. Imaging Instruments

5.2.2.2.1. CT Systems
5.2.2.2.2. Ultrasound Systems
5.2.2.2.3. MRI Systems
5.2.2.2.4. Mammography Systems
5.2.2.2.5. Nuclear Imaging Systems

5.2.3. Biopsy Instruments

Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis
6.1. by Technology & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Technology:

6.2.1. IVD Testing

6.2.1.1. Polymerase Chain Reaction (PCR)
6.2.1.2. In Situ Hybridization (ISH)
6.2.1.3. Immunohistochemistry (IHC)
6.2.1.4. Next-generation Sequencing (NGS)
6.2.1.5. Microarrays
6.2.1.6. Flow Cytometry
6.2.1.7. Immunoassays
6.2.1.8. Other IVD Testing Technologies

6.2.2. Imaging

6.2.2.1. Magnetic Resonance Imaging (MRI)
6.2.2.2. Computed Tomography (CT)
6.2.2.3. Positron Emission Tomography (PET)
6.2.2.4. Mammography
6.2.2.5. Ultrasound

6.2.3. Biopsy Technique

Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:

7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Melanoma
7.2.5. Other Cancers

Chapter 8. Market Segmentation 4: by End-user Estimates & Trend Analysis
8.1. by End-user & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-user:

8.2.1. Hospitals
8.2.2. Diagnostic Laboratories

Chapter 9. Cancer Diagnostics Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.1.2. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.1.3. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.1.4. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.1.5. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.2. Europe

9.2.1. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.2. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.3. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.4. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.2.5. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.3. Asia Pacific

9.3.1. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.2. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.3. Asia-Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.4. Asia-Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.3.5. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.4. Latin America

9.4.1. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.2. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.3. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.4. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.4.5. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.5. Middle East & Africa

9.5.1. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.2. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.3. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.4. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.5.5. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles


10.2.1. Abbott Laboratories,
10.2.2. Agilent Technologies Inc.,
10.2.3. AMOY Diagnostics Co Ltd.,
10.2.4. Astellas Pharma Inc. (Japan)
10.2.5. BD
10.2.6. BiocartisNV,
10.2.7. bioMérieux SA (France)
10.2.8. Bristol-Myers Squibb Company (U.S.)
10.2.9. Cancer Diagnostics Inc.,
10.2.10. Danaher Corporation,
10.2.11. DiagnoCure Inc. (Canada)
10.2.12. DiaSorin S.P.A.,
10.2.13. Excat Science
10.2.14. F. Hoffmann-La Roche Ltd.
10.2.15. FUJIFILM Corporation,
10.2.16. GE Healthcare
10.2.17. Genomic Health, Inc. (U.S.)
10.2.18. GSK plc. (U.K.)
10.2.19. Hologic, Inc.
10.2.20. Illumina, Inc.
10.2.21. Koninklijke Philips N.V. (Philips)
10.2.22. Lilly (U.S.)
10.2.23. Merck KGaA, (Germany)
10.2.24. Myriad Genetics Inc.,
10.2.25. Novartis AG (Switzerland)
10.2.26. Pfizer, Inc. (U.S.)
10.2.27. Qiagen N.V.
10.2.28. Quest Diagnostics Incorporated. (U.S.)
10.2.29. Quidel Corporation,
10.2.30. Roche Diagnostics,
10.2.31. Siemens Healthcare GmbH
10.2.32. Thermo Fisher Scientific, Inc.
10.2.33. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
6079
Security Code field cannot be blank!

Frequently Asked Questions

Cancer Diagnostics market Size is valued at 110.25 billion in 2024 and is predicted to reach 204.49 billion by the year 2034

Cancer Diagnostics Market expected to grow at a 6.5% CAGR during the forecast period for 2025-2034

GE Healthcare, Abbott Laboratories, Hologic Inc., Agilent Technologies Inc., Roche Diagnostics, FUJIFILM Corporation, Danaher Corporation, DiaSorin S.

Cancer Diagnostics market is segmented by product, technology, application, and end-user.

North American region is leading the Cancer Diagnostics Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying